archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Board of Directors | Agendia
    of the Dutch Participation Association NVP advising the Ministry of Economic Affairs on policy to stimulate early stage venture creation He is a member of the project screening committees at Dutch Universities He is currently on the boards of Acacia Pharma Agendia and BG Medicine Christoph Waer Supervisory Board Member member of the Audit Committee member of the Technical Committee and member of the Governance and Remuneration Committee Christoph is an investment manager at Korys focusing on the fund investments in the life science sector in both the private and public equity market In this capacity he currently represents Korys on the board of MyCartis Prior to that he was active as a Junior Analyst in the Paris offices of Fortis Bank now BNP Paribas at the Corporate Finance and Capital Markets department He then joined iPierian a San Francisco biotech start up company as a financial analyst Jan Willem Nieuwenhuize Supervisory Board Member member of the Governance Remuneration Committee and member of the Audit Committee Jan Willem Nieuwenhuize is an investment manager at ING Corporate Investments the equity investments branch of ING Bank Prior to joining ING in 2007 he worked for merchant bank Kempen Co in the M A and ECM team Erik Leeuwaarden Supervisory Board Member member of the Audit Committee Erik Leeuwaarden acquired a master degree in Law and Economics He started his career with the Dutch Ministery of Finance for twelve years Then he became CFO of Flowerauction FloraHolland from 1992 until 2014 He now advises and supervises companies in different fields as real estate finance IT and trade In 2015 Erik became a member of Agendia s Supervisory Board Peter Stein Supervisory Board Member member of the Governance Remuneration Committee Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of Norgine

    Original URL path: http://www.agendia.com/about/board-of-directors/ (2016-05-01)
    Open archived version from archive


  • Medical Advisory Board | Agendia
    Cytology for the evaluation of surgical margins Dr Cox has been recognized within the local and national press and was honored by his colleagues as a doctor s doctor is listed in Who s Who in America and sited in the Best Doctors in America Southeast Region In 1999 he was named Physician of the year at the Moffitt Cancer Center Dr Cox is also the Principle Investigator of Agendia s Multi Institutional Neo adjuvant Therapy MammaPrint Project I MINT Trial The MINT Trial is designed to test the ability of MammaPrint in combination with TargetPrint BluePrint and TheraPrint as well as traditional pathologic and clinical prognostic factors to predict responsiveness to neo adjuvant chemotherapy in patients with locally advanced breast cancer LABC Mark Gittleman M D Dr Mark Gittleman is a practicing breast surgeon in Allentown PA where he is the Medical Director of Breast Care Specialists and Advanced Breast Care Imaging He is a past President of the American Society of Breast Surgeons and serves on the ASBS Coding and Reimbursement and Breast Imaging Technology committees and is a review for Ultrasound and Stereotactic certification applicants Dr Gittleman is frequently an invited speaker on image guided breast surgery and other breast cancer related topics He is a faculty member of the ACS Post Graduate courses related to breast imaging and minimally invasive biopsy techniques Stephanie Akbari M D Dr Stephanie Akbari is the Medical Director of the Center for Breast Health at Virginia Hospital Center with an expertise in breast surgery A Phi Beta Kappa graduate of Mount Holyoke College and a graduate of the University of Pennsylvania School of Medicine Dr Akbari completed her surgical internship residency and chief residency at Harvard Medical School s Beth Israel Deaconess Hospital followed by a two year National Institutes of

    Original URL path: http://www.agendia.com/about/medical-advisory-board/ (2016-05-01)
    Open archived version from archive

  • Milestones | Agendia
    formalin fixed paraffin embedded FFPE tissue 2014 25 Year outcomes study Published Study Validates Agendia s MammaPrint Test for Long Term Prediction of Breast Cancer Outcome up to 25 years 2013 RASTER Published First ever PROSPECTIVE outcomes study for a breast cancer recurrence assay is published 2012 ColoPrint Launched 18 Gene Expression Profile for Colon Cancer Risk of Recurrence released to market 2010 Agendia Breast Cancer Test Suite The three assays MammaPrint BluePrint and TargetPrint are launched as a single suite of tests 2008 Dutch Guidelines Inclusion MammaPrint was selected and incorporated into the Dutch Institute CBO Guidelines for treatment of primary breast cancer 2007 First FDA Clearance MammaPrint received its first of six FDA clearances 2014 NBRST Study Published Researchers conclude BluePrint assay may serve as a better guide for physicians decisions about how to treat their patients early stage breast cancers before surgery 2013 BLUEPRINT SUBTYPING SHOWN TO BE MORE ACCURATE THAN IHC FISH The Glück et al paper showed that BluePrint Molecular Subtyping reclassified up to 25 of breast cancers with better response to neoadjuvant chemotherapy as compared to IHC FISH assessment 2012 MammaPrint available in FFPE MammaPrint BluePrint and TargetPrint assays are validated for formalin fixed paraffin embedded FFPE tissue 2010 BluePrint Assay Launched BluePrint 80 Gene Molecular Subtyping Assay is introduced to market 2009 St Gallen s Guidelines Inclusion MammaPrint is selected and included in the St Gallen s International Oncology Guidelines for treatment of early stage breast cancer 2008 TargetPrint Launched TargetPrint ER PR HER2 Expression Assay is launched to market 2004 MammPrint Launched MammaPrint 70 Gene Breast Cancer Recurrence Assay is launched as a commercial diagnostic product in Europe 2002 GENE EXPRESSION PROFILING DISCOVERY Drs Laura van t Veer and René Bernards publish the landmark discovery paper for MammaPrint in Nature Where we

    Original URL path: http://www.agendia.com/about/milestones/ (2016-05-01)
    Open archived version from archive

  • Awards & Recognition | Agendia
    a recipient of the 2011 Scrip Award for Best Partnership for its cooperative alliance between Agendia AstraZeneca and the Netherlands Cancer Institute NKI 2009 St Gallen s International Oncology Guidelines MammaPrint added to the St Gallen s International Oncology Guidelines for Primary Therapy of Early Breast Cancer 2008 Dutch Government s Healthcare Innovation Platform MammaPrint test declared One of the Most Pioneering Healthcare Innovations in the 21st Century by the Dutch Government s Healthcare Innovation Platform 2008 MammaPrint included in The Dutch Institute for Healthcare Improvement CBO Guidelines MammaPrint has been included in the updated 2008 guidelines of The Dutch Institute for Healthcare Improvement CBO The CBO guidelines drafted in collaboration with the Dutch Association of Comprehensive Cancer Centers ACCC and the Dutch National Breast Cancer Consultation Group NABON MammaPrint will be offered as standard of care for all eligible early stage breast cancer patients at the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital NKI AVL 2007 FDA Clearance The U S Food Drug Administration granted the first and only IVDMIA clearance to the MammaPrint breast cancer gene expression profile On June 22 Agendia acquired the second MammaPrint FDA clearance for use with its RNARetain room temperature tissue fixative for molecular testing 2007 Estee Lauder Dr Laura van t Veer Co founder and Chief Research Officer of Agendia received the 2007 Breast Cancer Research Foundation Award from the Estee Lauder Pink Ribbon Breast Cancer Research Foundation 2007 The Frost Sullivan European Product Innovation Award The Frost Sullivan European Product Innovation Award in the field of biomarker based breast cancer diagnostics was presented to Agendia for its new method of translating a breast cancer prognosis microarray signature into a high throughput diagnostic test called MammaPrint 2007 TIME Magazine TIME Magazine chose MammaPrint as one of the Five Best Healthcare Inventions of

    Original URL path: http://www.agendia.com/about/awards-and-recognition/ (2016-05-01)
    Open archived version from archive

  • Accreditations & Licenses | Agendia
    York PFI8448 Maryland 1673 US Food and Drug Administration FDA K101454 K141142 FFPE California Food and Drug Branch FDB 56461 LNE G MED ISO13485 2003 23899 The Netherlands Amsterdam Laboratory Agency Number CLIA 99D1030869 CAP 7194410 Declaration of Conformity MammaPrint DOC012012 Declaration of Conformity BluePrint DOC012014 Declaration of Conformity TargetPrint DOC012015 Declaration of Conformity ColoPrint DOC012013 LNE G MED ISO13485 2003 23899 We d Love To Hear From You Name

    Original URL path: http://www.agendia.com/our-science/accreditations-licenses/ (2016-05-01)
    Open archived version from archive

  • Investors & Press | Agendia
    and the increased market demand for molecular diagnostics With a pipeline of genomic products in development the company collaborates with pharmaceutical companies leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY 2 and the MINDACT trials Original shareholders include the founders of Agendia and Stichting Fondsen Nederland that originated from the Netherlands Cancer Institute Press

    Original URL path: http://www.agendia.com/investor-relations/ (2016-05-01)
    Open archived version from archive

  • News and Press Releases | Agendia
    change clinical practice by substantially de escalating the Continued MINDACT results will be presented during the AACR Annual Meeting 2016 04 01 2016 EORTC European Organisation for Research and Treatment of Cancer BIG Breast International Group and Agendia are pleased to announce that the Primary analysis of the EORTC 10041 BIG 3 04 MINDACT study a Continued Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings 03 08 2016 Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference MBCC IRVINE CA and AMSTERDAM Agendia Inc a world leader in personalized medicine and molecular cancer diagnostics announced Continued Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care 02 11 2016 Agendia is disappointed with the recent update to the American Society of Clinical Oncology ASCO Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material effect on the guidelines We Continued Agendia and Partners Receive 6 8 million from European Commission to Study Targeted Therapies for Colorectal Cancer 12

    Original URL path: http://www.agendia.com/agendia-news-and-press-releases/ (2016-05-01)
    Open archived version from archive

  • Collaborations | Agendia
    determine how these factors affect outcomes We are currently participating in three major prospective clinical studies MINDACT breast cancer I SPY2 breast cancer and PARSC colon cancer all of which are utilizing our MammaPrint or ColoPrint assay to pre select patient groups for particular cancer treatments Currently the results of our RASTER study are the first ever and only prospective outcome data that has been published for a breast cancer recurrence assay Biomarkers For Pathway targeted Therapies The identification of crucial signaling pathways has led to the development of targeted drugs designed to inhibit these pathways We have gathered gene expression and gene mutation data on thousands of colon cancer and breast cancer tissue samples and we can use this data in our discovery projects on particular genetic pathway signatures seeking to identify multiple key drivers of cancer cell behavior in various forms of cancer We have begun collaborations with certain major international pharmaceutical companies and academic partners to identify new biomarkers and develop new tests for predicting response to these targeted therapies in the treatment of breast colon and lung cancer In the course of these efforts we have begun to develop more sophisticated molecular diagnostics integrating multiple diagnostic strategies which we believe will lead to a new generation of multi index tests in molecular cancer diagnostics Collaborative Development Patient Sample To Diagnosis Process Enhancement Our business is built on the core competencies of our founders world renowned research and clinical experience in the field of genomics Agendia s culture is unique in terms of its unbiased scientific approach pairing the optimum methodologies with disruptive technologies to achieve ground breaking clinically meaningful results We apply a best in class approach to maintain a leadership position in the rapidly evolving field of molecular diagnostics We are committed to providing accurate

    Original URL path: http://www.agendia.com/our-science/collaborations/ (2016-05-01)
    Open archived version from archive



  •